Stock Details
4523.T is Eisai Co., Ltd.'s stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 6,080.96ï¿¥. Average daily volumn in 3 months 1.26M. Market cap 2.17T



Stock symbol : 4523.T. Exchange : Tokyo. Currency : JPY
Lastest price : 7,569.00ï¿¥. Total volume : 3.01M. Market state PREPRE
Click reload if you want to check the lastest price on market!!!

Eisai Co., Ltd. (4523.T)
Last Price
7,569.00ï¿¥
Change
105.00
Volume
3.01M

Previous Close7,464.00
Open7,400.00
Day Range7,392.00-7,579.00
Bid0.00 x N/A
Ask0.00 x N/A
Volume3.01M
Average Volume1.26M
Market Cap2.17T
Beta0.16
52 Week Range5,011.00-8,486.00
Trailing P/E45.26
Foward P/E40.86
Dividend (Yield %)2.11%
Ex-Dividend Date2023-03-30



Financial Details


According to Eisai Co., Ltd.'s financial reports the company's revenue in 2022 were 756.23B an increase( +17.21%) over the years 2021 revenue that were of 645.94B. In 2022 the company's total earnings were 47.95B while total earnings in 2021 were 42.12B( +11.9%).


Loading ...



Organization

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted... medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

eisai-co-ltd-logo

Market Cap:
2.17T
Revenue:
756.23B
Total Assets:
1.24T
Total Cash:
309.63B


News about "Eisai Co., Ltd."

eisai-completes-construction-of-its-new-injectionresearch-building-at-kawashima-industrial-park-in-japan-image

Eisai Completes Construction Of Its New Injection/Research Building At Kawashima Industrial Park In Japan

Source from : Mena FN - 1 days ago

Eisai Co., Ltd. announced that, as part of the strategic investment towards the realization of its medium-term business plan 'EWAY Future & Beyond', it has completed construction of the new ...See details»


Eisai Co., Ltd. (4523)

Source from : Investing - 2 days ago

During 2017 we expect updates on all three of SymBio’s main assets. We expect Treakisym sales growth via partner Eisai Co., Ltd. (T:4523) following approvals during 2016 in ...See details»


Alzheimer's drug study yields positive results, say makers Eisai and Biogen

Source from : Reuters - 6 days ago

Sept 27 (Reuters) - An experimental Alzheimer's drug made by Eisai Co Ltd (4523.T) and Biogen (BIIB.O) slowed cognitive and functional decline in a large trial of patients in the early stages of ...See details»


Factbox: FACTBOX Eisai-Biogen Alzheimer's drug success follows many failures

Source from : Reuters - 7 days ago

Sept 27 (Reuters) - Eisai Co Ltd (4523.T) and Biogen Inc (BIIB.O) reported late-stage data from their Alzheimer's disease drug lecanemab that showed it significantly slowed cognitive decline ...See details»


positive-results-from-eisai-and-biogen-alzheimers-trial-image

Positive results from Eisai and Biogen Alzheimer’s trial

Source from : labiotech - 6 days ago

Eisai and Biogen have announced positive results from a trial of lecanemab to treat mild cognitive impairment due to Alzheimer’s disease.See details»


alzheimers-drug-succeeds-in-slowing-cognitive-decline-say-eisai-and-biogen-image

Alzheimer's drug succeeds in slowing cognitive decline, say Eisai and Biogen

Source from : Khaleej Times on MSN - 7 days ago

The experimental remedy, lecanemab, slowed progress of the brain-wasting disease by 27%, as compared to a placebo ...See details»


Alzheimer’s drug study yields positive results in early stages of disease

Source from : Fox News - 7 days ago

An experimental Alzheimer's drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday ...See details»


eisais-lecanemab-confirmatory-phase-3-clarity-ad-study-met-primary-endpoint-image

Eisai's Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint

Source from : Asia One - 7 days ago

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced positive topline results from Eisai's large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab (development code: BAN2401), ...See details»


alzheimers-disease-eisai-and-biogen-release-milestone-data-image

Alzheimer's disease: Eisai and Biogen release milestone data

Source from : biopharma-reporter - 7 days ago

An investigational Alzheimer's drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a trial involving a large group of patients in the early stages of the disease.See details»


Alzheimer's drug shows promise in early results of study

Source from : ABC News - 7 days ago

Eisai Co. Ltd. said it would discuss full results from the research at a conference in late November. It also plans to publish findings in a peer-reviewed medical journal. The company is already ...See details»


Biogen And Eisai's Lecanemab Slows Progression Of Alzheimer's Disease In Phase 3 Trial

Source from : Nasdaq - 8 days ago

(RTTNews) - Biogen Inc. (BIIB) and Eisai Co., Ltd.'s investigational Alzheimer's disease drug lecanemab could potentially slow the progression of the disease in a large global Phase 3 clinical ...See details»


Eisai, Biogen say Alzheimer's drug succeeds in slowing cognitive decline

Source from : Nasdaq - 8 days ago

Sept 27 (Reuters) - An experimental Alzheimer's drug developed by Eisai Co Ltd 4523.T and Biogen Inc BIIB.O significantly slowed cognitive and functional decline in a large trial of patients in ...See details»


study-of-experimental-alzheimers-drug-yields-positive-results-makers-eisai-and-biogen-say-image

Study of experimental Alzheimer’s drug yields positive results, makers Eisai and Biogen say

Source from : The Globe and Mail - 7 days ago

Eisai and Biogen said that the experimental drug slowed cognitive and functional decline in a large trial of patients in the early stages of Alzheimer’s ...See details»


Alzheimer's drug shows promise in early results of study

Source from : The Independent - 6 days ago

Eisai Co. Ltd. said it would discuss full results from the research at a conference in late November. It also plans to publish its findings in a peer-reviewed medical journal. The company is ...See details»